Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta, is composed of an alpha and a beta sub-unit. The alpha sub-unit is essentially identical to the alpha sub-units of the human pituitary gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), as well as to the alpha sub-unit of human thyroid-stimulating hormone (TSH). The beta sub-units of these hormones differ in amino acid sequence.Chorionic Gonadotropin is a water soluble glycoprotein derived from human pregnancy urine. The sterile lyophilized powder is stable. When reconstituted with Bacteriostatic Water for Injection preserved with benzyl alcohol 0.9%, the solution should be refrigerated and used within 30 days.Each vial contains:Chorionic Gonadotropin 10,000 USP Units, Mannitol 100 mg, Dibasic Sodium Phosphate 16 mg, and Monobasic Sodium Phosphate 4 mg.
Novarel (Chorionic Gonadotropin) is indicated for the following:
HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR “NORMAL” DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS.
Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9.
Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males.
Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.
Published Studies Related to Novarel (Chorionic Gonadotropin)
The effect of low dose human chorionic gonadotropin on follicular response and oocyte maturation in PCOS patients undergoing IVF cycles: a randomized clinical trial of efficacy and safety. [2011.12]
PURPOSE: To compare the efficacy of two regimens of low dose human chorionic gonadotropin (hCG) on follicular response and oocyte maturation in women with polycystic ovarian syndrome (PCOS)... CONCLUSIONS: A combination of FSH and low dose hCG improved oocyte maturity and preserved outcomes with improved safety and lowered cost.
Is earlier administration of human chorionic gonadotropin (hCG) associated with the probability of pregnancy in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone (GnRH) antagonists? A prospective randomized trial. [2011.11]
OBJECTIVE: To evaluate the association of timing of hCG administration and probability of pregnancy in patients stimulated with recombinant FSH/GnRH antagonists for IVF...
Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. [2011.05]
OBJECTIVE: To detect differences in follicular fluid (FF) levels of amphiregulin (AR), depending on mode of triggering final oocyte maturation.
Follicle-stimulating hormone administered at the time of human chorionic gonadotropin trigger improves oocyte developmental competence in in vitro fertilization cycles: a randomized, double-blind, placebo-controlled trial. [2011.04]
OBJECTIVE: To determine whether an additional follicle-stimulating hormone (FSH) bolus administered at the time of the human chorionic gonadotropin (hCG) trigger can improve the developmental competence of the oocyte.
The effect of gonadotropin withdrawal and stimulation with human chorionic gonadotropin on intratesticular androstenedione and DHEA in normal men. [2011.04]
INTRODUCTION: Concentrations of intratesticular (IT) testosterone (T) are known to be 100-200 times those of serum T; however, the IT concentrations of T's precursors, their testicular to serum gradients, gonadotropin dependence, and response to stimulation with human chorionic gonadotropin (hCG) have not been studied in detail...
Clinical Trials Related to Novarel (Chorionic Gonadotropin)
Comparison of Micro-dose Human Chorionic Gonadotropin (hCG) With Human Menopausal Gonadotropin (HMG) in Polycystic Ovary Syndrome [Recruiting]
The purpose of this study is to compare the effectiveness of low dose human chorionic
gonadotropin (HCG) in combination with clomiphen citrate to induce ovulation and its
endocrine response in patients who had previously failed to ovulate on clomiphen citrate
alone. The investigators will also compare the effectiveness and endocrine response of this
approach with the regimen of adding HMG to clomiphen citrate.
Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders [Not yet recruiting]
In an era of delayed fertility plans, there is increasing need for fertility treatment in
older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to
treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.
Triggering of Final Oocyte Maturation With GnRHa (Buserelin) in GnRH Antagonist Cycles [Recruiting]
The purpose of this study is to possibly further improve the clinical outcome and explore
the incidence of OHSS in patients, who have final oocyte maturation with GnRHa (Buserelin)
in GnRH antagonist IVF/ICSI cycles
Evaluation of the Luteolytic Effect of a Gonadotropin Releasing Hormone (GnRH) Agonist After the Administration of Human Chorionic Gonadotropin (hCG) in the Initial Follicular Phase a Its Influence on the Prognosis of in Vitro Fertilization Treatment [Recruiting]
This study was designed to evaluate the ability of gonadotropin releasing hormone (GnRh)
agonist to prevent the rise of progesterone during controlled ovarian stimulation for in
vitro fertilization (IVF) after the administration of human Chorionic Gonadotropin (hCG) on
the first day of menses.
Effect of hCG on Receptivity of the Human Endometrium [Recruiting]
Worldwide, 1 in 12 couples experience difficulty in getting pregnant and seek the help of
assisted reproductive technologies (ART) such as in vitro fertilization (IVF-egg is
fertilized by sperm outside the body), ovarian stimulation (medications are used to
stimulate egg development) and intra-cytoplasmic injection (ICSI-single sperm is injected
directly into the egg).
Regardless of the ART procedure being performed, the newly fertilized embryo must still
implant into the mothers endometrium (inner lining of uterus). This implantation process in
humans is surprisingly inefficient and accounts for up to 50% of ART failures. Intrauterine
infusion of hCG prior to embryo transfer has recently been shown to increase pregnancy rates
but the cellular mechanism for this increase is unknown.
Successful implantation requires the newly fertilized embryo and the endometrium develop in
a synchronized manner. This coordinated development is accomplished, in part, by proteins
secreted by the embryo which circulate throughout the maternal bloodstream and alert the
maternal body organs (i. e. ovary, endometrium, breast, ect) that fertilization has occurred.
One of the earliest of these secreted proteins is human chorionic gonadotropin (hCG), which
is the molecule detected in over-the-counter pregnancy tests. From previous studies, we know
that hCG production by the embryo alerts the ovary to continue producing progesterone, a
hormone required for pregnancy. However, very little is known about the direct effect of hCG
on the endometrium during early pregnancy in humans.
Using animal models, hCG has been shown to induce specific changes in the endometrium,
suggesting that embryo-derived hCG may be "priming" the endometrium in anticipation of
implantation. The goal of this research study is to examine the direct effect of hCG on the
human endometrium and see if this "priming effect" is also present in humans. Findings from
this research may reveal whether pre-treatment with hCG can enhance ART outcomes, especially